From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Hip and Knee Ops Are in Mighty Demand though this British Tech-Med Titan Seems Undervalued - As Yet

By Malcolm Stacey | Thursday 17 March 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Hello Share Finders. There’s evidence the share world hasn’t yet woken to the prospect of a better future for big medical companies. All that coverage on tv is just one example of how interest in the field is gaining. I imagine many kids now want to be doctors or nurses. And the majority of folks in Britain say they’re happier to pay higher taxes to support the NHS. A company that will do well out of extra dosh being pumped into health services around the world is Smith and Nephew (SN.).

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 21:35:35